Ketamine Eases Suicidal Thoughts, But Does It Save Lives?

What the Review Found

A new analysis published in Psychiatric Times on September 29, 2026, tackles a question that shapes crisis care decisions every day: do ketamine, esketamine, and electroconvulsive therapy (ECT) actually prevent suicide, or do they only ease the thoughts that come before it? According to the publication, all three treatments can rapidly reduce suicidal thoughts, in some cases within hours, but the evidence that they prevent suicide attempts or deaths remains limited. That gap between symptom relief and outcome prevention is the core of the debate, and it matters for anyone comparing these treatments during or after a mental health crisis. Read the original analysis at Psychiatric Times.

Ketamine is a dissociative anesthetic used off-label at sub-anesthetic doses, usually by IV infusion, to rapidly reduce depressive and suicidal symptoms. Esketamine, marketed as Spravato, is a nasal spray version of one part of the ketamine molecule that carries FDA approval for treatment-resistant depression and, since 2020, an added indication for depressive symptoms in adults with major depressive disorder who have suicidal ideation or behavior. ECT delivers a brief, controlled electrical current under anesthesia to induce a seizure and remains one of the fastest-acting treatments psychiatry has for severe, treatment-resistant depression with active suicidality. All three have a documented track record of lowering scores on suicidal ideation scales within hours to days.

Why Fewer Suicidal Thoughts Doesn't Prove Fewer Suicides

The distinction the review highlights comes down to what clinical trials can realistically measure. Suicidal ideation is tracked with self-report scales, so a drop in score reflects what a patient reports thinking or feeling in the moment. Suicide attempts and deaths are, thankfully, rare events at the population level, which means a study would need a very large sample and years of follow-up to detect a meaningful change in that specific outcome. Most ketamine and esketamine trials run from 24 hours to a few weeks, and few are designed or powered to track attempts or deaths as an endpoint. ECT has a longer research history, but the same statistical challenge applies to any treatment being tested against a rare, high-stakes outcome.

This does not mean the treatments fail to protect patients. It means the type of evidence needed to prove attempt or death prevention, large randomized trials with years of follow-up and attempts or deaths as the primary measured outcome, does not yet exist in the volume researchers would need to draw a firm conclusion either way. Absence of that evidence is not the same as evidence that the treatments don't work at the outcome level; it is a documentation gap that the field has not yet closed.

What to Ask Before Starting Treatment

If you or someone you're supporting is considering ketamine, esketamine, or ECT specifically for suicidal thoughts, a few questions can help set realistic expectations. Ask the provider what outcome they're tracking: most clinics measure ideation scores, not longer-term attempt or death rates, and understanding that distinction helps you interpret your own progress accurately. Ask what happens after the acute stabilization window closes, since a rapid drop in suicidal thoughts over hours or days does not replace ongoing therapy, medication management, or a written safety plan. Esketamine's FDA-approved pathway for suicidal ideation includes a required in-office observation period of about two hours per REMS (Risk Evaluation and Mitigation Strategy) monitoring rules, while IV ketamine protocols for suicidality vary by clinic since most such use is off-label. ECT typically requires inpatient or closely monitored outpatient settings given the anesthesia involved, and is generally reserved for the most severe or treatment-resistant cases.

Cost and access also differ sharply across the three options. Esketamine is covered by many insurance plans under its approved indications but requires REMS-certified clinics. IV ketamine clinics are more widely available but often bill out of pocket, with per-session costs and protocols varying by provider. ECT is typically delivered in hospital-affiliated settings and covered similarly to other inpatient psychiatric procedures. None of these logistics change the underlying evidence question the Psychiatric Times review raises, but they shape how quickly and affordably a patient in crisis can actually access rapid relief.

What Comes Next for the Research

Closing the evidence gap the review describes will likely require registries and longer-term follow-up studies that track patients for months or years after treatment, not just the days immediately following a ketamine infusion or ECT course. Until larger, longer-duration data exists, clinicians and patients are left weighing strong short-term symptom evidence against an open question on the outcome that matters most. For readers comparing treatment options today, the practical stance is straightforward: these therapies can meaningfully ease suicidal thoughts fast, which can be lifesaving in itself during a crisis, but they work best as part of a broader safety plan that includes therapy, medication follow-up, and support from family or crisis services, not as a standalone substitute for it.